India, March 04, 2025: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian manufacturer of injectable drugs, has received its first ever global marketing authorization for Sugammadex from the Philippines. This approval marks a major step in the company’s expansion into complex generics, reinforcing its commitment to high-value, technology-intensive formulations and expanding its foothold in the ASEAN market.

Sugammadex is a selective relaxant-binding agent (SRBA) used for the rapid reversal of neuromuscular blockade induced by rocuronium and vecuronium—two commonly used muscle relaxants in anesthesia. Unlike traditional agents, Sugammadex directly encapsulates and inactivates these drugs, offering a faster, safer, and more predictable recovery from anesthesia, reducing the risk of post-operative respiratory complications.

The global Sugammadex market, valued at approximately 1.53 billion in 2023, is projected to grow at a CAGR of 8.5%, reaching USD 2.89 billion by 2031.

Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre shared, “There is a growing demand for advanced surgical care and high-growth therapeutic segments in the Philippines which makes this approval particularly relevant. Venus Remedies holds marketing authorizations for several crucial drugs in the Philippines. Sugammadex represents our entry into high-barrier-to-entry complex generics, and we are committed to ensuring equitable access to such advanced medicines globally".

Overall, the pharmaceutical market in the ASEAN region is projected to grow at a CAGR of 4.83% from 2025 to 2029. With its state-of-the-art manufacturing facilities, Venus Remedies is poised to capture a significant share in the Philippines and the wider ASEAN region.

“As a company committed to affordable access to cutting-edge medicines, our expansion into complex injectables and critical care drugs aligns with our long-term vision. The approval of Sugammadex is part of a broader strategy to penetrate both regulated and emerging markets, reinforcing our position in the high-growth ASEAN region", said Mrs. Aditi Chaudhary, President, International Business, Venus Remedies.

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP. Apart from GMP accreditations, other approvals related to Quality Management (ISO 9001:2015), Environment Management (ISO 14001: 2015), Occupational Health & Safety Management (ISO 45001:2018) are maintained. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 138 patents worldwide and having more than 75 registered trademarks and more than 15 copyrights for its innovative research products.  Moreover, in 2025, Venus Remedies received recognition as a ‘Great Place to Work’ for the fourth consecutive time.